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Abstract A backbone-caged sperm-activating peptide (caged
speract) that has a 2-nitrobenzyl group at a backbone amide
and a vastly reduced a⁄nity for its receptor (IC50 = 950 nM)
was synthesized. UV irradiation of caged speract photocleaves
the 2-nitrobenzyl group (d1=2 = 26 Ws), restoring its a⁄nity
(IC50 = 0.67 nM) and ability to increase sperm intracellular
pH and Ca2+, as intact speract. Backbone caging of the biolog-
ical activity was more e⁄cient than side chain caging, which
adds a nitrobenzyl group on the peptide side chain. The back-
bone caging strategy described can be used as a general proce-
dure to cage biologically active peptides, which have no side
chain for introduction of a caging group. 0 2002 Federation
of European Biochemical Societies. Published by Elsevier Sci-
ence B.V. All rights reserved.
Key words: Caged peptide; Speract; Backbone amide; Sperm
1. Introduction
Caged peptides and proteins, whose activities are masked
by the introduction of photocleavable groups, have recently
been recognized as a useful tool to elucidate various biological
phenomena with a high spatial and temporal resolution, even
in living cells. This is because active molecules can be gener-
ated at a desired time and position in a sample specimen by
carrying out a photochemical reaction using pulsed and fo-
cused UV light irradiation, respectively [1,2]. Photocleavable
groups have been introduced on the side chains [3^8], the
N-terminal amino group [9] and C-terminal carboxyl group
[10] of biologically active peptides. To provide a caging e¡ect,
the photocleavable groups need to be incorporated exactly
into the active site of the target peptide. However, it is not
always easy to ¢nd a site of incorporation, because an active
site residue is not always at a position where it is possible to
incorporate the photocleavable group. To overcome this lim-
itation, we report here on the synthesis of caged peptides that
have a 2-nitrobenzyl group, a photocleavable group, on the
backbone amide of a polypeptide main chain. By using this
method, we have synthesized a potent caged sperm-activating
peptide (SAP or speract). SAPs are di¡usible components of
the echinoderm egg jelly coat [11] that show various biological
e¡ects on homologous spermatozoa [12]. Speract (or SAP-1)
Gly-Phe-Asp-Leu-Asn-Gly-Gly-Gly-Val-Gly from a sea ur-
chin was the ¢rst SAP to be puri¢ed and structurally identi¢ed
[13]. A speract binds to its receptor on the sperm £agella,
transiently activating a guanylate cyclase and inducing
changes in intracellular pH (pHi) and Ca2þ ([Ca2þ]i) [12].
The development of caged speracts will o¡er a useful tool to
investigate underlying events.
2. Materials and methods
2.1. Reagents and materials
Fmoc L-amino acids, resins and reagents used for the peptide syn-
thesis were obtained from Shimadzu (Kyoto, Japan). Fmoc-caged
serine and lysine were obtained from the Peptide Institute (Osaka,
Japan). Fmoc amino acid £uorides were prepared according to the
reported method [14]. 2P,7P-bis-(2-Carboxyethyl)-5-(and-6)-carboxy-
£uorescein, acetoxymethyl ester (BCECF-AM) and £uo-3-AM were
obtained from Molecular Probes (Eugene, OR, USA). 6-(Fluorescein-
5-(and-6)-carboxamido)hexanoyl speract (F-speract) was prepared as
described in a previous paper [15]. Sperm was obtained as previously
described from Strongylocentrotus purpuratus [15].
2.2. N-K-Fmoc-N-K-2P-nitrobenzyl-glycine
A solution of 2-nitrobenzaldehyde (33.2 g, 0.22 mol) in 100 ml of
methanol was added to glycine (15.02 g, 0.2 mol) in 50 ml of methanol
and 50 ml of 2 N NaOH. After 1 h stirring at room temperature,
NaBH4 (6.0 g, 0.63 mol) was added to the solution at 0‡C. After 2 h,
the solution was evaporated and washed with diethyl ether. Then the
pH of the aqueous phase was adjusted to about 5 with HCl and
washed with diethyl ether. Thereafter, the aqueous phase was evapo-
rated to give crude N-2P-nitrobenzyl-glycine. Recrystallization from
water gave 12.3 g of the pure compound. A solution of 1.5 equivalent
of £uorenylmethyloxy carbonyl chloride (3.89 g, 15 mmol) in 20 ml of
acetone was added to N-2P-nitrobenzyl-glycine (2.24 g, 10 mmol) in 30
ml of 10% NaHCO3, 70 ml of water and 80 ml of acetone. The so-
lution was stirred overnight at room temperature. After evaporation
of the acetone, the suspension was washed three times with ether. The
pH was adjusted to about 4 with HCl. Ethyl acetate was added to the
solution and the organic phase was separated, washed with water and
dried over sodium sulfate. Re-precipitation with hexane gave 4.04 g
(yield 94%) of the target compound as white solid. Fast atom bom-
bardment mass spectrometry calculated for C24H20N2O6 : 432.43;
[M3] m/z found: 432.09.
2.3. Peptide synthesis
Peptides were synthesized using an automated peptide synthesizer
(PSSM-8, Shimadzu, Kyoto, Japan) by Fmoc chemistry. Fmoc amino
acids were activated with benzotriazolyloxy-tris-pyrrolidino-phospho-
nium hexa£uorophosphate (one equivalent), hydroxybenzotriazole
(one equivalent) and N-methylmorpholin (1.5 equivalents) in dimeth-
ylformamide. The serine next to the N-2P-nitrobenzyl glycine was
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activated with diisopropyl carbodiimide (10 equivalents) and N-meth-
ylmorpholin (1.5 equivalents) in dimethylformamide. A 10-fold excess
of the activated amino acid was added to the resin. The target pep-
tides were puri¢ed by reversed phase high-performance liquid chro-
matography (HPLC) and identi¢ed by time-of-£ight mass spectrome-
try (TOF-MS; MALDI TOF mass spectrometer, Kratos, Manchester,
UK). Molecular weight of the puri¢ed peptides agreed with the calcu-
lated values within the acceptable errors; e.g. [Ser5, NB-Gly5] speract:
TOF-MS calculated for C44H60N11O16 : 999.91; [M+Hþ] m/z found:
1003, [M3NB+Hþ] m/z found: 867. The fraction containing the de-
sired peptide was lyophilized.
2.4. Study of the binding of speract to the receptor
F-speract (0.5 nM) was mixed with various concentrations of sper-
act analogs in a glass tube (2 ml of sea water) and incubated with
spermatozoa for 1 h. Since the bound F-speract emits little £uores-
cence due to quenching, the fraction of free F-speract can be deter-
mined by measuring the total £uorescence intensity of each sample
without any mechanical separation of the bound and free ligands [15].
The £uorescence intensity was recorded on a spectro£uorometer
(Aminco SLM 8000, SLM Instruments, IL, USA). The UV photolysis
of the caged peptide was carried out at V=254 nm light with an UV
crosslinker (Stratalinker, Stratagene, IL, USA).
2.5. Laser £ash photolysis
A solution of the sample in a quartz cell was irradiated with the
third harmonic light pulse of a Nd:YAG laser (SureLite II, Contin-
uum, Santa Clara, CA, USA; pulse width, 8 ns; energy, 38 mJ; wave-
length, 355 nm). The transient absorption during the laser irradiation
was measured using a photomultiplier tube and monochromatic light
of 420 nm from a 150 W xenon lamp. The photocurrent was fed into
an oscilloscope (TDS340AP, Sony-Tektronics, Tokyo, Japan) and the
data were transferred to a computer. All the peptide was prepared as
a 1 mM solution in N-tris(hydroxymethyl) methyl-2-aminoethanesul-
fonic acid (2.5 mM, pH 7.0) containing 40% acetonitrile.
2.6. Sperm pHi and [Ca
2+]i measurements
Dry sperm was suspended in 5^10-fold of LC7SW (low Ca2þ pH
7.0 sea water), and incubated with 20 WM of BCECF-AM or 25 WM
of £uo-3-AM plus 0.4% Pluronic F-127 at 14‡C for 3 h. The indica-
tor-loaded sperm was washed with LC7SW by centrifugation
(1000Ug for 7 min), re-suspended in the original volume of LC7SW
and kept on ice until used. Photolysis of the caged speract was
achieved using an UV £ash lamp system (JML-C2, Rapp Opto Elec-
tronic, Hamburg, Germany) with an UV bandpass ¢lter (270^400 nm)
connected to the spectro£uorometer.
3. Results
3.1. Synthesis of backbone-caged peptide
Acylation of N-2P-nitrobenzyl glycine with the use of phos-
phonium reagents was unsuccessful due to the N-alkyl group,
but acylation using acyl £uorides or carbodiimides did suc-
ceed. Therefore, the serine next to the N-2P-nitrobenzyl glycine
was activated with the use of diisopropyl carbodiimide. The
2-nitrobenzyl group on the backbone amide, i.e. the backbone
cage, was stable against treatment with base (30% piperidine
in dimethylformamide) and acid (85% tri£uoroacetic acid).
The backbone-caged speract, [Ser5, NB-Gly6] speract, was
obtained as the single dominant product, without signi¢cant
by-products (Fig. 1).
3.2. Receptor binding and photolysis study
The biological activity was examined by the inhibition of
binding of the F-speract to the receptor (Fig. 2). [Ser5] speract
inhibited the speci¢c binding of F-speract to the speract re-
ceptor very e¡ectively (IC50 = 0.67 nM), but the introduction
of the backbone cage resulted in signi¢cant loss of inhibitory
activity (IC50 = 950 nM). UV irradiation of the backbone-
caged speract produced the intact peptide, [Ser5] speract,
which was con¢rmed by mass spectrometry and HPLC. The
UV irradiation also resulted in the recovery of the inhibitory
activity to the same level as that of the intact [Ser5] speract
(the inset of Fig. 2). The kinetics of photolysis were examined
measuring the transient absorption of the intermediate (Fig.
3). The half-life of the decrease of the photolysis intermediate,
i.e. the production rate of the intact peptide, was calculated to
be 26.0 Ws.
3.3. Sperm pHi and [Ca
2+]i measurements
The binding of speract to the receptor transiently activates
a guanylate cyclase and triggers the signaling pathways.
Fig. 1. Scheme of synthesis and photolysis of backbone-caged speract. a: (i) Nitrobenzaldehyde, NaBH4 ; (ii) Fmoc-Cl. b: Solid phase peptide
synthesis. c: UV irradiation.
Fig. 2. Competitive binding activity of the caged and decaged sper-
acts. Spermatozoa were incubated in sea water for 1 h with 0.5 nM
of F-speract and various concentrations of [Ser5, NB-Gly6] speract
(caged form), or [Ser5] speract (decaged form). The £uorescence in-
tensity (Vex = 494 nm, Vem = 524 nm, the free fraction of F-speract)
was plotted against the concentration of the caged speract (open
circles) and the decaged speract (closed circles). Each point is the
mean of four measurements ( S S.D.). The inset shows the recovery
of the activity of the caged speract (1 WM) as a function of UV
irradiation time. The dotted line indicates the activity for the intact
peptide (1 WM).
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Noted e¡ects are increases in pHi [16] and [Ca2þ]i [17]. As
shown in Fig. 4, an UV £ash evoked a signi¢cant increase
in both sperm pHi and [Ca2þ]i only in the presence of the
backbone-caged speracts. The UV £ash by itself did not pro-
duce any deleterious e¡ect on sperm as judged by its capacity
to respond to decaged speracts.
3.4. Side chain-caged peptide
We also synthesized side chain-caged speracts (Table 1).
Introduction of a caged residue at the second, sixth and sev-
enth positions resulted in a decrease in the inhibitory activity,
but the analog substituted at the sixth position was excluded
as a caged precursor since the intact form was inactive. The
half-life of the decrease of the photolysis intermediate for the
serine-caged speracts was as long as that for the backbone-
caged peptide, but the lysine-caged and tyrosine-caged sper-
acts showed slower rates.
4. Discussion
One of the indispensable properties for useful caged com-
pounds pointed out by Kaplan and Somlyo [1] is that the
caged compound precursor should be biologically inactive
or, at least, some orders of magnitude less active than the
photolysis product, since caged compounds are added prior
to photolysis. The backbone cage was shown to exert a pro-
nounced e¡ect on the speci¢c competitive binding activity of
the peptide to the receptor. The IC50 of the caged form was
about three orders of magnitude higher than that of the de-
caged form. Two peptides among the side chain-caged speracts,
the [Tyr(NB)2] and [Ser(NB)7] speracts, could be used as
caged speracts, but the di¡erence in the activity between the
caged and decaged forms was less than two orders of magni-
tude (Table 1). In this respect, the backbone-caged speract is
much more useful than the side chain-caged speracts.
Another necessary property for useful caged compounds is
that the photolysis reaction should be su⁄ciently fast [1]. The
photolytic process is thought to proceed through a mechanis-
tic pathway that includes (i) photoinduced oxygen transfer
from the nitro group to the benzylic carbon position, and
the formation of the aci-nitro compound, and (ii) hemiacetal
decomposition and furnishment of the free amide [18]. Pulsed
Fig. 3. Changes in absorption of [Ser5, NB-Gly6] speract caused by a pulse of UV light. The average of results from eight experiments is
shown. The inset illustrates the reaction scheme of photolysis, where R1 and R2 represent the peptide fragments, Gly-Gly-Gly-Val-Gly and
Gly-Phe-Asp-Leu-Ser, respectively.
Table 1
Inhibition of speci¢c binding of F-speracts to the receptor (IC50) and kinetics (k1=2) during the photolysis of the caged peptides
Caged peptide IC50 (nM) k1=2 (Ws) Intact peptide IC50 (nM)
speract 0.66
Backbone-caged speract
[Ser5, NB-Gly6] speract 950 26.0 [Ser5] speract 0.67
Side chain-caged speracts
[Tyr(NB)2] speract 179 123.7 [Tyr2] speract 2.78
[Lys(NBoc)3] speract 0.74 1299.6 [Lys3] speract n.d.
[Ser(NB)5] speract 7.22 34.4 [Ser5] speract 0.67
[Ser(NB)6] speract 4900 36.9 [Ser6] speract 1062
[Ser(NB)7] speract 71.8 25.0 [Ser7] speract 1.05
[Ser(NB)8] speract 0.59 26.1 [Ser8] speract n.d.
[Ser(NB)10] speract 0.64 10.9 [Ser10] speract 0.76
n.d.: not determined.
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UV light causes a rapid increase and a single exponential
decay in the absorption at 420 nm, which can be ascribed
to the formation of the aci-nitro intermediate. The half-life
of the intermediate during photolysis of the [Ser5, NB-Gly6]
speract was calculated to be 26.0 Ws, indicating that the time
resolution achieved is as fast as that of the side chain-caged
speracts and faster than that allowed by stopped-£ow tech-
niques [19].
The pHi and [Ca2þ]i measurements in live sperm shown in
Fig. 4 indicate that the backbone-caged speract can be used
for in vivo experiments without any problems that may arise
from the side-products of photolysis or photodamage to the
cell. A second £ash induced a smaller response, probably ow-
ing to the saturation or desensitization of the receptor. These
results clearly indicate that the backbone-caged peptide is a
useful tool to study speract response. Time-resolved measure-
ments of pHi, [Ca2þ]i and motility using this caged speract
will contribute to our understanding of sperm physiology.
The advantage of the backbone-caged peptide is that this
strategy provides various sites for the introduction of a photo-
cleavable group, whereas the side chain-caged peptide has an
obvious limitation in the variety of amino acid residues for the
introduction of a photocleavable group. A native speract has
no site for the introduction of a photocleavable group by
using an Fmoc derivative of caged Tyr, Lys, Ser or Cys that
we have prepared in our laboratory. We therefore chose, judg-
ing from the previous results of the structure^activity relation-
ship [11,20], the side chain residues for substitution to make
the caged speract.
To the best of our knowledge, and among the caged pep-
tides prepared by us, the backbone caged peptides show the
greatest caging e¡ect. The glycine at the sixth position in
speracts is considered to be essential for the activity of this
peptide because only this position is conserved among all
speract isoforms (s 50) puri¢ed from various species of sea
urchin [11]. In fact, in our experiment, the [Ser6] speract shows
remarkably low competitive binding activity (Table 1). In ad-
dition, Nomura and Isaka synthesized various speract analogs
with substitutions and deletions, and showed that the activity
of the [Pro6] speract is very low, suggesting that the amide
bond 5N6 is important for receptor binding [20]. Taking all
information into account, we introduced the 2-nitrobenzyl
group at the amide bond between the ¢fth and sixth positions.
Studies using N-substituted analogs of biologically active pep-
tides show that the conformational freedom of the substituted
residue is highly restricted and that analogs have the potential
of assuming a cis peptide bond [21,22]. Therefore, one possi-
ble reason for the decrease in the binding activity of the back-
bone-caged peptide is that the conformational constraints in-
troduced via the 2-nitrobenzyl group are unfavorable for
binding to the receptor. Another possibility is that the block-
age of intermolecular hydrogen bonding sites by the N sub-
stitution restricts protein^protein interactions. Such intermo-
lecular hydrogen bonding is found to be very important for
the tight binding of peptide antigens in class I MHC mole-
cules [23].
In conclusion, we have developed a simple method for the
synthesis of backbone-caged peptides that satisfy the require-
ments for useful caged compounds. This method is applicable
to any peptide sequence, whereas for the synthesis of side
chain-caged peptides, substitution of the native amino acid
sequence, which may alter important properties such as selec-
tivity for receptor subtypes, is sometimes necessary, as exem-
pli¢ed by the present study.
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Fig. 4. Sperm responses to UV £ashes in the presence or absence of
caged speracts. Time courses of sperm pHi (A) and sperm [Ca2þ]i
(B) were measured £uorometrically using BCECF (Vex = 500 nm,
Vem = 525 nm)- and £uo-3 (Vex = 505 nm, Vem = 525 nm) -loaded
sperm. Upward changes of the £uorescence intensity indicate an in-
crease in pHi and [Ca2þ]i, respectively. The sperm suspension was
irradiated using an UV £ash lamp, as indicated by the arrows. Con-
tinuous lines show sperm responses in the presence of 1 WM of
[Ser5, NB-Gly6] speracts, and dotted lines indicate control experi-
ments in the absence of [Ser5, NB-Gly6] speracts. The large noise at
the UV £ash was due to scattering.
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